CIAS
RGNX icon

Capital Investment Advisory Services’s Regenxbio RGNX Stock Holding History

Capital Investment Advisory Services’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-200
Closed -$10K – 1450
2019
Q2 		$10K Buy
+200
New +$9.98K ﹤0.01% 974

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Investment Advisory Services's RGNX Position: Q3 2019 in Review

Capital Investment Advisory Services sold out of Regenxbio (RGNX) in Q3 2019, closing a stake of 200 shares — an estimated $10K sold.

Capital Investment Advisory Services first reported a position in RGNX in Q2 2019 and held it in 1 quarter. The position peaked at $10K in Q2 2019. 168 funds tracked by Wall St. Rank hold RGNX as of Q3 2019.

  • Capital Investment Advisory Services reported no remaining Regenxbio position as of Q3 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 200 Regenxbio shares in Q3 2019, an estimated $10K.
  • Capital Investment Advisory Services first reported a position in Regenxbio in Q2 2019 and held it in 1 quarter.
  • Capital Investment Advisory Services's Regenxbio position peaked at $10K in Q2 2019.
  • 168 funds tracked by Wall St. Rank held Regenxbio as of Q3 2019.

Based on Capital Investment Advisory Services's 13F filing for Q3 2019, filed 17 Oct 2019.